Drug interactions
Eribulin + Inotuzumab
Severity: Major
Eribulin and Inotuzumab: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Both agents are associated with QT interval prolongation. Concurrent use may add to the effect and increase the risk of serious ventricular arrhythmia.
What this interaction means in plain words
Eribulin and Inotuzumab can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Why it happens
Additive pharmacodynamic QT prolongation.
What to do
Avoid concurrent use if alternatives exist. If unavoidable, obtain ECG and electrolytes before starting and periodically during treatment, and replace potassium and magnesium as needed.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Eribulin and Inotuzumab, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Eribulin
Frequently asked questions
Can I take Eribulin with Inotuzumab?
MediHelp rates the interaction as major. Eribulin and Inotuzumab can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Both agents are associated with QT interval prolongation. Concurrent use may add to the effect and increase the risk of serious ventricular arrhythmia.
How serious is the interaction between Eribulin and Inotuzumab?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid concurrent use if alternatives exist. If unavoidable, obtain ECG and electrolytes before starting and periodically during treatment, and replace potassium and magnesium as needed.
What other medicines interact with Eribulin?
MediHelp also lists interactions of Eribulin with, for example, Adagrasib, Amiodarone, Amisulpride. The full list is on the Eribulin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
